The revamped business development model at AstraZeneca plc (LSE:AZN; NYSE:AZN) has embedded dedicated business development groups into therapeutic areas at all stages of development. The Innovative Medicine and Early Development (iMED) business development leaders coordinate the sourcing of partnering opportunities for small molecules from discovery through Phase I. For oncology and other